Moberg Pharma AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.08.20	Moberg Pharma: Interim report April - June 2020 (PR Newswire)
30.07.20	Appointment of Chief Medical Officer at Moberg Pharma (PR Newswire)
30.06.20	New number of Shares and Votes in Moberg Pharma AB (publ) (PR Newswire)
25.06.20	Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study (PR Newswire)
25.06.20	Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study (PR Newswire)
29.05.20	New Number of Shares and Votes in Moberg Pharma AB (publ) (PR Newswire)
12.05.20	Extended Fiscal Year July 2019 - December 2020 Interim Report January - March 2020 (PR Newswire)
05.05.20	Moberg Pharma's Interim Report for July 2019 - March 2020 to be Published on May 12 - Invitation to Teleconference (PR Newswire)
27.03.20	Notice of Extraordinary General Meeting in Moberg Pharma AB (publ) (PR Newswire)
23.03.20	Moberg Pharma Enters Financing Agreement of Up To SEK 216 Million for Further Investments in MOB-015 (PR Newswire)
11.02.20	Moberg Pharma AB Interim Report October - December 2019 (PR Newswire)
04.02.20	Moberg Pharma's Interim Report to be Published on February 11 - Invitation to Teleconference (PR Newswire)
22.01.20	Expert Evaluation Clarifies Phase 3 Results and Provides Strong Support for MOB-015 (PR Newswire)
12.12.19	Moberg Pharma Comments on the Results of the North American Phase 3 Study With MOB-015 (PR Newswire)
09.12.19	Moberg Pharma Meets Primary Endpoint for MOB-015 in a Phase 3 Study for the Treatment of Onychomycosis (PR Newswire)
17.11.19	Ausblick: Moberg Pharma AB gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
30.10.19	Bulletin from Moberg Pharma's AGM on October 30th, 2019 (PR Newswire)
21.10.19	Moberg Pharma and DongKoo Sign Agreement for MOB-015 in the Republic of Korea (PR Newswire)
18.10.19	Changes to Moberg Pharma's Management Team (PR Newswire)
30.09.19	Moberg Pharma Proposes to pay the Shareholders SEK 46.50 per Ordinary Share and Repays the MOB-015 Loan (PR Newswire)
30.09.19	Moberg Pharma Proposes to pay the Shareholders SEK 46.50 per Ordinary Share and Repays the MOB-015 Loan (PR Newswire)
30.09.19	Moberg Pharma and Taisho Sign Exclusive License Agreement for MOB-015 in Japan (PR Newswire)
30.09.19	Moberg Pharma and Taisho Sign Exclusive License Agreement for MOB-015 in Japan (PR Newswire)
15.05.19	Bulletin from Moberg Pharma's AGM 2019 (PR Newswire)
14.05.19	Moberg Pharma AB Interim Report January - March 2019 (PR Newswire)
13.05.19	Ausblick: Moberg Pharma AB veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
16.04.19	Moberg Pharma Annual Report 2018 (PR Newswire)
08.04.19	Proposed Management Changes at Moberg Pharma (PR Newswire)
08.04.19	Moberg Pharma: The Nomination Committee's Proposal to the Annual General Meeting 2019 (PR Newswire)
01.04.19	Moberg Pharma Gives Notice of Early Redemption of Bonds With ISIN SE0007953989 (PR Newswire)
29.03.19	Moberg Pharma Completes the Divestment of the OTC-business for USD 155 million (PR Newswire)
29.03.19	Moberg Pharma Completes the Divestment of the OTC-business for USD 155 million (PR Newswire)
22.03.19	Moberg Pharma Completes Enrollment for MOB-015 Phase 3 Study in Europe (PR Newswire)
15.03.19	Bulletin from Moberg Pharma's Extraordinary General Meeting 15 March 2019 (PR Newswire)
04.03.19	Moberg Pharma Publishes Information Document on the Proposed Divestment of the OTC-Business (PR Newswire)
13.02.19	Notice of Extraordinary General Meeting in Moberg Pharma AB (publ) (PR Newswire)
12.02.19	Moberg Pharma AB Year-end Report 2018 (PR Newswire)
12.02.19	Moberg Pharma Divests Its OTC-business for USD 155 Million and Secures New Funding for MOB-015 in Transformational Transaction (PR Newswire)
11.02.19	Moberg Pharma and Bayer Sign Exclusive License Agreement for MOB-015 in Europe (PR Newswire)
11.02.19	Moberg Pharma and Bayer Sign Exclusive License Agreement for MOB-015 in Europe (PR Newswire)
11.02.19	Ausblick: Moberg Pharma AB gewährt Anlegern Blick in die Bücher (finanzen.net)
05.11.18	Ausblick: Moberg Pharma AB stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)
15.05.18	Bulletin from Moberg Pharma's AGM 2018 (PR Newswire)
08.05.18	Moberg Pharma AB Interim Report January - March 2018 (PR Newswire)
02.05.18	U.S. Patent Granted for BUPI (PR Newswire)
27.04.18	Moberg Pharma Completes Divestment of Balmex® for $4.25 million (PR Newswire)
19.04.18	Management Change in Moberg Pharma (PR Newswire)
10.04.18	Moberg Pharma Annual Report 2017 (PR Newswire)
13.03.18	The Nomination Committee's Proposal to the Annual General Meeting 2018 (PR Newswire)
28.02.18	Moberg Pharma Divests Balmex® for $4.25 Million (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Lonza Grp	606.00	1.41 %	K V
Logitech Intl	89.42	0.90 %	K V
Zurich Insur Gr	557.00	0.69 %	K V
ABB	49.35	0.65 %	K V
Swiss Re	139.30	0.32 %	K V
Novartis	95.59	-0.52 %	K V
Swisscom	506.00	-0.78 %	K V
Kuehne+Nagel Int	201.60	-0.79 %	K V
Sonova Hldg	305.20	-3.42 %	K V
UBS Group	29.55	-7.05 %	K V

Nachrichten zu Moberg Pharma AB

Aktien Top/Flop

Meistgelesene Nachrichten